[1] Carnero Contentti E, Daccach Marques V, Soto de Castillo I, Tkachuk V, Antunes Barreira A, Armas E, Chiganer E, de Aquino Cruz C, Di Pace JL, Hryb JP, Lavigne Moreira C, Lessa C, Molina O, Perassolo M, Soto A, Caride A.Short-segment transverse myelitis lesions in a cohort of Latin American patients with neuromyelitis optica spectrum disorders[J].Spinal Cord, 2018, 56:949-954.
[2] Murphy OC, Mukharesh L, Salazar-Camelo A, Pardo CA, Newsome SD.Early factors associated with later conversion to multiple sclerosis in patients presenting with isolated myelitis[J].J Neurol Neurosurg Psychiatry, 2021.[Epub ahead of print]
[3] Lopez Chiriboga S, Flanagan EP.Myelitis and other autoimmune myelopathies[J].Continuum (Minneap Minn), 2021, 27:62-92.
[4] Abbatemarco JR, Galli JR, Sweeney ML, Carlson NG, Samara VC, Davis H, Rodenbeck S, Wong KH, Paz Soldan MM, Greenlee JE, Rose JW, Delic A, Clardy SL.Modern look at transverse myelitis and inflammatory myelopathy:epidemiology of the national veterans health administration population[J].Neurol Neuroimmunol Neuroinflamm, 2021, 8:e1071.
[5] Filippi M, Preziosa P, Banwell BL, Barkhof F, Ciccarelli O, De Stefano N, Geurts JJG, Paul F, Reich DS, Toosy AT, Traboulsee A, Wattjes MP, Yousry TA, Gass A, Lubetzki C, Weinshenker BG, Rocca MA.Assessment of lesions on magnetic resonance imaging in multiple sclerosis:practical guidelines[J].Brain, 2019, 142:1858-1875.
[6] Fang W, Zheng Y, Yang F, Cai MT, Shen CH, Liu ZR, Zhang YX, Ding MP.Short segment myelitis as the initial and only manifestation of aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorders[J].Ther Adv Neurol Disord, 2020, 13:1756286419898594.
[7] Ciron J, Cobo-Calvo A, Audoin B, Bourre B, Brassat D, Cohen M, Collongues N, Deschamps R, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Zephir H, Bereau M, Brochet B, Carra-Dallière C, Derache N, Gagou-Scherer C, Henry C, Kerschen P, Mathey G, Maubeuge N, Maurousset A, Montcuquet A, Moreau T, Prat C, Taithe F, Thouvenot E, Tourbah A, Rollot F, Vukusic S, Marignier R.Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies:a retrospective multicentric study[J].Mult Scler, 2020, 26:936-944.
[8] Alvarenga MP, Thuler LC, Neto SP, Vasconcelos CC, Camargo SG, Alvarenga MP, Papais-Alvarenga RM.The clinical course of idiopathic acute transverse myelitis in patients from Rio de Janeiro[J].J Neurol, 2010, 257:992-998.
[9] Gajofatto A, Monaco S, Fiorini M, Zanusso G, Vedovello M, Rossi F, Turatti M, Benedetti MD.Assessment of outcome predictors in first-episode acute myelitis:a retrospective study of 53 cases[J].Arch Neurol, 2010, 67:724-730.
[10] Li R, Qiu W, Lu Z, Dai Y, Wu A, Long Y, Wang Y, Bao J, Hu X.Acute transverse myelitis in demyelinating diseases among the Chinese[J].J Neurol, 2011, 258:2206-2213.
[11] Schee JP, Viswanathan S.Pure spinal multiple sclerosis:a possible novel entity within the multiple sclerosis disease spectrum[J].Mult Scler, 2019, 25:1189-1195.
[12] Neuroimmunology Branch, Chinese Society of Immunology.Chinese guidelines for the diagnosis and treatment of neuromyelitis optica spectrum disorders (2021 edition)[J].Zhongguo Shen Jing Mian Yi Xue He Shen Jing Bing Xue Za Zhi, 2021, 28:423-436.[中国免疫学会神经免疫分会.中国视神经脊髓炎谱系疾病诊断与治疗指南(2021版)[J].中国神经免疫学和神经病学杂志, 2021, 28:423-436.]
[13] Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.MOG encephalomyelitis:international recommendations on diagnosis and antibody testing[J].J Neuroinflammation, 2018, 15:134.
[14] Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.Diagnosis of multiple sclerosis:2017 revisions of the McDonald criteria[J].Lancet Neurol, 2018, 17:162-173.
[15] Kunchok A, Zekeridou A, McKeon A.Autoimmune glial fibrillary acidic protein astrocytopathy[J].Curr Opin Neurol, 2019, 32:452-458.
[16] Dubey D, Hinson SR, Jolliffe EA, Zekeridou A, Flanagan EP, Pittock SJ, Basal E, Drubach DA, Lachance DH, Lennon VA, McKeon A.Autoimmune GFAP astrocytopathy:prospective evaluation of 90 patients in 1 year[J].J Neuroimmunol, 2018, 321:157-163.
[17] Xiao J, Chen X, Shang K, Tang Y, Chen M, Deng G, Qin C, Tian DS.Clinical, neuroradiological, diagnostic and prognostic profile of autoimmune glial fibrillary acidic protein astrocytopathy:a pooled analysis of 324 cases from published data and a single-center retrospective study[J].J Neuroimmunol, 2021, 360:577718.
[18] Zekeridou A, McKeon A, Flanagan EP.A path to understanding autoimmune GFAP astrocytopathy[J].Eur J Neurol, 2018, 25:421-422.
[19] Iorio R, Damato V, Evoli A, Gessi M, Gaudino S, Di Lazzaro V, Spagni G, Sluijs JA, Hol EM.Clinical and immunological characteristics of the spectrum of GFAP autoimmunity:a case series of 22 patients[J].J Neurol Neurosurg Psychiatry, 2018, 89:138-146.
[20] Shan F, Long Y, Qiu W.Autoimmune glial fibrillary acidic protein astrocytopathy:a review of the literature[J].Front Immunol, 2018, 9:2802.
[21] Fang B, McKeon A, Hinson SR, Kryzer TJ, Pittock SJ, Aksamit AJ, Lennon VA.Autoimmune glial fibrillary acidic protein astrocytopathy:a novel meningoencephalomyelitis[J].JAMA Neurol, 2016, 73:1297-1307. |